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Abstract
Objective To evaluate the perfusate and systemic kinetics
of oxaliplatin during hyperthermic intraperitoneal chemo-
therapy (HIPEC) using a selective analytical technique.
Methods HIPEC was carried out in eight patients by the
open abdomen coliseum technique for 30 min at 41.5-43°C
with an average of 427 mg/m2 of oxaliplatin in 5% dextrose
solution. Blood and perfusate samples were collected
during the perfusion. Additional blood samples were taken
up to 2 h after the end of perfusion. The analysis was
performed by liquid chromatography and post-column
derivatization with N,N-diethyldithiocarbamate using
microwave heating.
Results The mean elimination half-life of oxaliplatin in the
perfusate was 29.5 min (range 21.1-41.2 min) and in the
peripheral circulation 24.7 min (range 21.7-27.7 min).
The ratio of the areas under the time concentration curve
in perfusate and blood was 12.8±2.9.
Conclusion The systemic exposure of oxaliplatin measured
after HIPEC using a selective analytical technique is con-
siderably lower than previously reported results obtained by
atomic absorption spectroscopy.
Keywords Intraperitoneal chemotherapy . Hyperthermia .
Pharmacokinetics . Oxaliplatin
Introduction
Peritoneal carcinomatosis (PC) from colorectal cancer
implies a poor prognosis [1–3]. However, in selected
patients, peritonectomy followed by oxaliplatin-based hy-
perthermic intraperitoneal chemotherapy (HIPEC) has in
some cases been curative and has in the majority of cases
prolonged survival [4, 5]. Oxaliplatin, a third-generation
antineoplastic platinum complex, is currently used in the
treatment of advanced colorectal cancer. Previous kinetic
studies of oxaliplatin during HIPEC have been based on the
use of atomic absorption spectroscopy (AAS), an unselec-
tive analytical technique measuring the total platinum
content in plasma ultrafiltrate or plasma [6, 7]. This method
will codetermine oxaliplatin and platinum (Pt)-containing
cytotoxic and biologically inactive biotransformation
products.
A method for quantitative determination of the free
fraction of intact oxaliplatin in blood ultrafiltrate has been
developed [8] and applied to pharmacokinetic studies in
humans [9–11]. The results establish that oxaliplatin has a
drastically shorter terminal elimination half-life than was
suggested based on results obtained by AAS, 15 min vs.
32–47 h respectively [12].
The aim of this study was to analyse the free fraction of
intact oxaliplatin in peritoneal perfusate and blood after
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Eight patients with PC who underwent peritonectomy
and oxaliplatin-based HIPEC at the Uppsala University
Hospital were included. The regional ethics committees
approved the study and informed consent was obtained
from each patient.
There were five women and three men of mean age
56 (range 39–64) years (Table 1). The primary tumour
types were colorectal adenocarcinoma (CRC) (4), recur-
rent epithelial ovarian cancer (3) and gastric adenocarci-
noma (1). The eligibility requirements for treatment were
as follows: histologically confirmed diagnosis of PC; no
distant metastases; adequate renal, haematopoietic and
liver functions; and WHO performance status ≤2. How-
ever, one patient with CRC had associated liver metastases
treated by right-sided hemihepatectomy during the same
procedure.
HIPEC
Oxaliplatin was given using the coliseum technique as
described by Sugerbaker [13]. Briefly, a Tenckhoff inflow
catheter is placed centrally in the abdomen and four outflow
catheters are inserted through separate stab incisions in the
abdominal wall. Both the inflow and outflow catheters are
connected to a perfusion pump and heat exchanger. The
skin of the abdomen is attached to a retractor ring, and the
abdominal cavity is covered with a plastic sheet with a
small opening in the centre allowing entrance for the
surgeon’s hands to stir the abdominal contents resulting in a
better exposure of the intraabdominal surfaces and a more
uniform distribution of drug and heat. The dose of
oxaliplatin (460 mg/m2) was planned according to the
findings of Elias [6]. However, since all patients had
received a preoperative neo-adjuvant chemotherapy prior
to peritonectomy and HIPEC, the patients received a
reduced dose (mean 427 mg/m2) and also concomitant iv
5-FU (500 mg/m2) plus iv calcium levofolinate (30 mg/m2).
The body surface area determined the volume of the carrier
solution and electrolyte-free glucose (50 mg/ml) was used
for oxaliplatin perfusion. The duration of the perfusion was
30 min as described by Elias [6]. Prior to the start of
perfusion, the patients were cooled to 35°C with a cooling
blanket. The intraabdominal temperature during perfusion
ranged from 41.5 to 43°C. In all patients, four intra-
abdominal drains were left in place after surgery.
Perfusate and blood sampling
Perfusate and arterial blood (2 ml) were drawn before
HIPEC and at 2, 5, 10, 15, 20 and 30 min during the
perfusion. Additional peripheral blood was collected at 1,
15, 30, 60, 90 and 120 min after the end of the
perfusion.
Oxaliplatin analysis
Handling of the blood samples and liquid chromatographic
analysis were performed according to a procedure de-
scribed previously [8]. Briefly, blood was collected in
prechilled Vacutainer tubes, stored on ice and dispensed in
prechilled Centrisart tubes. The samples were ultrafiltrated
centripetally at 4°C within 30 min from sampling (4,000×g,
20 min). The ultrafiltrates were promptly frozen on dry ice
stored at -80°C and analysed within 3 weeks. Oxaliplatin
was separated on a Hypercarb S column using a mobile
phase of methanol/succinic acid buffer 0.25 M, pH



















1 57 M 69 1.84 22.3 CRC 25 840 457 3.2
2 64 F 68 1.72 26.2 Ovarian 25 780 453 3.2
3 54 F 86 2.06 26.5 Ovarian 26 920 447 4.2
4 56 M 80 2.02 23.9 CRC 40 925 459 3.2
5 59 F 55 1.58 21.0 CRC 32 615 389 2.1
6 57 F 65 1.73 23.3 CRC 30 690 399 3.1
7 59 F 60 1.72 20.0 Ovarian 27 700 407 4.1
8 39 M 84 1.96 28.7 Gastric 27 800 408 2.7
Mean±SD 56±7 71±11 1.83±0.17 24.0±3.0 29±5 784±111 427±29 3.2±0.7
SA Surface area, BMI body mass index, EVF erythrocyte volume fraction, CRC colorectal adenocarcinoma
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7.0 (9/1 v/v), with a flow rate of 0.5 ml/min. The
postcolumn derivatization was performed by mixing the
mobile phase with 2.7 mM N,N-diethyldithiocarbamate in
methanol (flow: 0.17 ml/min) followed by microwave
heating (SmithCreator) in Teflon tubing (2 m). The
quantification was carried out by photometric detection at
344 nm.
Standard curves in blood were prepared by adding
oxaliplatin to blood with the same EFV as the patient to
be analysed. The standards (0.1–25 μM) were ultrafiltrated
and treated in the same way as the patient samples.
Perfusate samples were treated as blood, and standards
were prepared in distilled water. Before LC analysis, the
perfusate samples were diluted 100 times with water.
Samples from blood and perfusate were always run in
parallel with the corresponding standards.
In vitro degradation of oxaliplatin in perfusate
from treated patients
A portion of the perfusate samples (n=6) from each
patient were mixed, promptly placed on dry ice and stored
at -80°C for no more than 1 week until the study was
performed. The degradation rate of oxaliplatin in each
perfusate mixture was determined at 43°C. The analysis
was carried out as described above. The degradation rate
constants were used to correct for the chemical degrada-
tion in the perfusate when calculating the dose of
oxaliplatin absorbed.
Pharmacokinetic and statistical evaluation
The area under the blood ultrafiltrate (UF) concentration
(AUC) time curves was determined by the trapezoidal rule.
Time for infusion of saline to rinse the peritoneal cavity
was considered to be the stop time of perfusion. The
terminal elimination half-lives in blood-UF were evaluated
from 15 min after perfusion stop until the last sampling
time.
The area under the perfusion time curves was integrated
under the fitted curve, extrapolated to time zero and
perfusion stop time.
The correlation between body mass index (BMI) and
percent oxaliplatin absorbed was evaluated by Spearman
rank correlation. Mann-Whitney test (two-tailed) was
used when comparing blood ultrafiltrate half-life and
clearance during HIPEC with previous data after iv
administration [11]. The iv group consisted of eight
patients with similar gender distribution, age and weight
who received 130 mg/m2 of oxaliplatin over 30 min. For
all calculations and statistical analysis Prism for Windows,
version 3.0 (GraphPad Software, San Diego, CA, USA)
was used. P values <0.05 were taken as significant.
Results
Surgical treatment
The peritonectomy was performed as described by
Sugerbaker [14]. The extent of tumour load and com-
pleteness of surgical resection were immediately recorded
postoperatively using the Peritoneal Cancer Index (PCI)
and Completeness of Cytoreduction Score (CC) respec-
tively [15]. The PCI categorizes lesion size scores in 13
different regions of the abdomen: 0=no visible tumour,
1=tumour up to 0.5 cm, 2=tumour up to 5 cm and 3=
tumour >5 cm. The maximum PCI is 39. The CC score is
based on the size of tumour remnants after cytoreduction:
0=no peritoneal seeding visible, 1=nodules up to 2.5 mm,
2=nodules up to 2.5 cm and 3=nodules >2.5 cm.
The mean operating time was 9.4±1.9 h with a mean
blood loss of 763±302 ml (range 400–1,200 ml). Mean PCI
was 21 (range 6–37). Complete cytoreduction (CC-0) was
achieved in four patients, CC-1 in three and CC-2 in one
patient.
Pharmacokinetics
Perfusate and blood ultrafiltrate concentrations from the
patients are given in Fig. 1. The elimination half-lives in the
perfusate and the percentage of dose absorbed are given in
Table 2. The mean half-life was 29.5 min and the mean
absorbed amount was 48.4%. The amount absorbed was
corrected for chemical degradation in the perfusate during
the perfusion (5–10%). The ratio of the found initial
concentration of oxaliplatin in the perfusate and the
expected concentration taking into account the dose and
volume of perfusate was 0.9. The ratio Cmax perfusate/Cmax
blood ultrafiltrate was 28.4 and the ratio of AUC perfusate
Fig. 1 Perfusate (open circles) and blood ultrafiltrate (filled circles)
concentrations following administration of oxaliplatin
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to AUC blood ultrafiltrate was 12.8 (Table 2). There was a
positive correlation (P=0.028) between the BMI of the
patients and the percentage of oxaliplatin absorbed (Fig. 2).
The mean elimination half-life in the peripheral circulation
was 24.7 min, and the total body clearance 28.4 l h−1 m−2.
Discussion
The pharmacokinetics of oxaliplatin during HIPEC has so
far only been studied using the unselective analytical
technique of AAS measuring the total platinum content
[6, 7]. Since oxaliplatin rapidly reacts with endogenous
sulphur compounds [16] forming a variety of reaction
products, AAS will overestimate the concentration of the
active drug. The present paper gives an evaluation of the
kinetics of oxaliplatin during HIPEC using a selective
analytical technique measuring only the parent drug [8] and
comparing the results with previous data after iv adminis-
tration using the same technique [11].
The ratio of the intraperitoneal and systemic exposure
was 12.8 showing a local regional advantage of the drug in
this setting. The elimination of oxaliplatin from the
peritoneal compartment involves absorption to the general
circulation, reaction with solid tissues in the peritoneum [6]
and chemical degradation in the perfusate solution. The rate
of degradation varied among the patients (5-10%) as
established by the in vitro studies, most probably due to
differing amounts of red blood cells in the perfusate (cf.
[9]). The mean elimination half-life in the perfusate and the
percent dose absorbed were in general agreement with
previous results [6, 7], which is to be expected since the
major Pt-containing agent in the perfusate is intact
oxaliplatin. Patients with higher BMI showed increased











































































































































































































































































































































































































































































































































































































































Fig. 2 Correlation between the percentage of oxaliplatin absorbed
and body mass index
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The systemic exposure of oxaliplatin was about four
times lower than previously reported in studies analysing
ultrafiltrated platinum by using AAS [6, 7]. This is due to
the fact that, with time, intact oxaliplatin will constitute a
gradually decreasing fraction of total ultrafiltrated Pt due to
its high chemical reactivity with endogenous compounds
[16].
The blood ultrafiltrate AUC after HIPEC was about two
times higher than our previous data showed after iv
administration of 130 mg/m2 over 30 min [11]. The blood
elimination half-life was longer (P=0.0002) and the total
body clearance shorter (P=0.0047) than previous results
after iv administration [11]. The reason for this is not quite
clear but prolonged half-life and decreased clearance have
been reported during anaesthesia and have been attributed
to decreased hepatic flow and/or decreased glomerular
filtration rate [17].
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